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Human immunodeﬁciency virus type 1 (HIV-1) has a well-
recognized ability to acquire resistance to antiviral compounds both
in vitro and in vivo, as a result of its high replication rate combined
with an error-prone reverse transcriptase enzyme (Cofﬁn, 1996;
Hirsch et al., 2008). Randomly generated variants with a selective
advantage over their wild type counterparts therefore expand to
dominance in the presence of the selecting agent. Sometimes, the
genetic pathways involved can be unexpected, particularly for
resistance to compounds that affect the function of the env gene
products, the gp120 and gp41 envelope glycoproteins. Both these
proteins retain their abilities to mediate virus-cell entry in the face of
substantial sequence variation, more so for the surface gp120 than the
transmembrane gp41 subunit. When drug-resistant variants are
selected for, this functional plasticity is exploited and viruses with
unusual properties emerge.
We have been studying how variants resistant to the small
molecule CCR5 inhibitors arise in vitro. These compounds, exempliﬁedby the licensed drug maraviroc (MVC) and the drug candidate
vicriviroc (VCV), bind to the CCR5 co-receptor that is part of the virus-
cell entry pathway (Kuhmann and Hartley, 2008). By doing so, they
prevent gp120 from contacting CCR5 properly, and thereby abort the
sequence of conformational changes in the gp120–gp41 complex that
are essential for the virus and cell membranes to fuse together
(Kuhmann and Hartley, 2008). When HIV-1 is cultured for prolonged
periods in the presence of the CCR5 inhibitors, fully resistant variants
emerge that still use CCR5 to enter cells, by virtue of acquiring the
ability to interact with the inhibitor–CCR5 complex, while still
retaining the ability to use the free form of CCR5 (Pugach et al.,
2007; Westby et al., 2007).
The most common genetic pathway to resistance involves the
accumulation of several (usually two to four) sequence changes in the
V3 region of the gp120 glycoprotein (Baba et al., 2007; Kuhmann et al.,
2004; Laakso et al., 2007; Ogert et al., 2008; Tsibris et al., 2008;
Westby et al., 2007), a location that is consistent with the highly
variable nature of V3 and its role in CCR5 binding (Hartley et al., 2005;
Kuhmann and Hartley, 2008). The resistance phenotype of isolate
CC101.19, for example, has been attributed to four substitutions in V3
(K305R, H308P, A316V and G321E), with the proline at position 308
being the most critical determinant of resistance (Kuhmann et al.,
2004; Trkola et al., 2002). These V3 changes have been suggested to
render the virus more dependent on the CCR5 N-terminus, to
compensate for impaired interactions between the V3-crown and
the second extracellular loop (ECL2) (Berro et al., 2009). Consistent
with this concept are studies showing that substantial deletions in V3
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antagonists, presumably by disrupting the interaction between V3
and ECL2 (Agrawal-Gamse et al., 2009; Laakso et al., 2007; Lin et al.,
2007; Nolan et al., 2009, 2008). Increases in the afﬁnity of resistant
viruses for CD4 and/or in the kinetics of virus entry may compensate
for any adverse effect the V3 sequence changes have at the CCR5-
binding stage (Agrawal-Gamse et al., 2009; Platt et al., 2010). There is,
however, considerable complexity involved in the altered virus–CCR5
interactions. Thus, a subtype D, VCV-resistant patient isolate recog-
nizes the drug-bound form of CCR5 more efﬁciently but still uses both
the N-terminus and ECL2 (Ogert et al., 2010). Moreover, a model has
been proposed suggesting that broad cross-resistance to multiple
inhibitors is associated with an increased dependence on the
N-terminus, while a more speciﬁc pattern of resistance to individual
compounds involves more subtle changes in how the virus interacts
with both the N-terminus and ECL2 (Tilton et al., 2010).
We have also described a CCR5 inhibitor-resistant variant, D1/85.16,
that contains no sequence changes in V3 (Marozsan et al., 2005), and in
which resistance is conferred by three conservative substitutions in the
fusion peptide (FP) region of gp41 (Anastassopoulou et al., 2009). How
FP changes contribute to viral escape from VCV remains to be
understood; one possibility is that they may alter the rate or location
of fusion events.
Here, we describe the resistance genetics of another resistant
virus, D101.12, which was generated from a weakly resistant isolate,
CC101.6, under the selection pressure of VCV (Marozsan et al., 2005).
The CC101.6 virus itself emerged when the parental, inhibitor-
sensitive isolate CC1/85 was cultured for 6 passages in the presence
of AD101, a compound in the same general family as VCV (Trkola et al.,
2002). Compared to its parent, CC1/85, the CC101.6 isolate contains an
amino acid change in V3, H308P, that renders it up to 4-fold less
sensitive to such small molecules as AD101 and VCV (Kuhmann et al.,
2004). After 12 additional passages with VCV, the resulting D101.12
isolate became fully resistant (N20,000-fold). We show here that two
different gp41 lineages co-exist in the D101.12 isolate and clones
derived from it, together with at least the H308P substitution in V3.
Mutagenesis studies on clones derived from the D101.12 isolate show
that strong resistance to VCV can be conferred when the H308P
sequence change in V3 is combined with speciﬁc changes in the
N-terminal region of gp41, including, but not limited to, the FP. Hence
the two subunits of the Env complex can cooperate to enable a VCV-
resistant virus to use the VCV–CCR5 complex for entry.Table 1
Nomenclature and properties of viruses used in this study.
Virus Type Origin
gp120
CC1/85 Parental isolate NA
CC101.6 Input isolate NA
D101.12 (R#) VCV-resistant isolate (reversion isolate#) NA
S Parental clone CC1/85
S+(G514V) Mutant parental clone CC1/85
S+(G514V, V535M) Mutant parental clone CC1/85
S+(M518V, F519L) Mutant parental clone CC1/85
S+(M518V, F519L, V535M) Mutant parental clone CC1/85
S+(V535M) Mutant parental clone CC1/85
R14 VCV-resistant clone D101.1
R14/S Chimera D101.1
R14/S+(G514V) Mutant chimera D101.1
R14/S+(G514V, V535M) Mutant chimera D101.1
R14/S+(M518V, F519L) Mutant chimera D101.1
R14/S+(M518V, F519L, V535M) Mutant chimera D101.1
R14/S+(V535M) Mutant chimera D101.1
NA, not applicable.
# Isolates designated as D101.12R followed by a number were derived from the PBMC cu
number indicates the number of weekly passages (see Fig. 2B).
⁎ Amino acid numbering is based on HXB2 Env. The columns list the origins of gp120 and gp
and D101.12 (D101.12 cl.14 = R14). Isolate CC101.6 and clone R14 both contain the critical HResults
D101.12 is a VCV-resistant virus with a stable phenotype
Two fully resistant isolates were generated, from different input
viruses, under the selection pressure of VCV in vitro (for virus
nomenclature see Table 1 and Fig. 1). Isolate D1/85.16 emerged after
16 passages of the parental, inhibitor-sensitive CC1/85 isolate, while
D101.12 arose from the weakly resistant CC101.6 isolate after 12
passages (Marozsan et al., 2005). An infection–inhibition assay using
PBMC conﬁrmed the VCV sensitivities of the study viruses; the
CC101.6 isolate was weakly resistant, with a low (b5%), but
consistent, level of replication occurring even at very high inhibitor
concentrations (up to 5 μM). In contrast, D101.12, like D1/85.16, was
completely resistant to VCV (Fig. 2A).
To determine whether its VCV resistance phenotype was stable, we
returnedD101.12 to culture inPBMC for 19weeklypassageswithoutVCV,
assessing its inhibitor sensitivity periodically. Each virus from this
reversion culture, like the input D101.12 isolate, was completely resistant
to VCV concentrations as high as 5 μM, whereas the input CC101.6 virus
was again only weakly resistant (Fig. 2B). Hence, the D101.12 phenotype
is highly stable in a PBMC culture, with no associated ﬁtness cost. In this
respect, D101.12 resembles the fully AD101- and VCV-resistant CC101.19
and D1/85.16 isolates (Anastassopoulou et al., 2009; Anastassopoulou
et al., 2007).
Analysis of gp120 sequences
An infectious clone derived from the fully resistant D101.12
isolate, D101.12 cl.14 (= R14), retained the H308P change in V3 that
was also present in the CC101.6 input virus but had no other V3
changes compared to the parental isolate, CC1/85 (Kuhmann et al.,
2004; Marozsan et al., 2005). The introduction of the H308P single
residue change into a parental, inhibitor-sensitive clone is known to
confer low-level (~3-fold) resistance to AD101 and VCV (Kuhmann
et al., 2004). However, although the H308P change itself only
modestly affects VCV sensitivity, it has a substantial inﬂuence on the
outcome of additional V3 substitutions in this genetic context. Thus,
the three later-arising V3 changes (K305R, A316V and G321E) confer
complete resistance when introduced into a weakly resistant clone
that contains proline at residue 308, but they have no effect on VCV
sensitivity when the residue at this position is the predominantof env subunits in clones Engineered gp41
mutations (⁎)
gp41 sequence pattern
gp41
NA NA NA
NA NA NA
NA NA Patterns I and II (Pattern II )
cl.6 CC1/85 cl.6 NA NA
cl.6 CC1/85 cl.6 G514V Pattern I
cl.6 CC1/85 cl.6 G514V, V535M Pattern I
cl.6 CC1/85 cl.6 M518V, F519L Pattern II
cl.6 CC1/85 cl.6 M518V, F519L, V535M Pattern II
cl.6 CC1/85 cl.6 V535M Patterns I and II
2 cl.14 D101.12 cl.14 NA Pattern I
2 cl.14 CC1/85 cl.6 NA NA
2 cl.14 CC1/85 cl.6 G514V Pattern I
2 cl.14 CC1/85 cl.6 G514V, V535M Pattern I
2 cl.14 CC1/85 cl.6 M518V, F519L Pattern II
2 cl.14 CC1/85 cl.6 M518V, F519L, V535M Pattern II
2 cl.14 CC1/85 cl.6 V535M Patterns I and II
lture in which D101.12 was cultured for a prolonged period in the absence of VCV; the
41 subunits in chimeric viruses based on the reference clones of CC1/85 (CC1/85 cl.6= S)
308P change in the gp120 V3 region.
Fig. 1. Passage history and associated genetics of CCR5 inhibitor-resistant viruses. The passage history, including passage numbers and culture conditions, of the escape mutant
viruses is depicted schematically, together with a summary of the speciﬁc genetic changes associated with resistance and relevant citations.
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proline at position 308, but it lacks the three later-arising resistance-
associated changes in V3 (Kuhmann et al., 2004; Marozsan et al.,
2005). Hence, additional mutations elsewhere in env must be critical
determinants of the full resistance of the D101.12 virus.
To map the responsible changes, we ﬁrst sequenced the env genes
from the D101.12 isolate and also from the VCV-resistant D101.12R7,
D101.12R8, D101.12R10 and D101.12R19 viruses that were derived
from the D101.12 reversion cultures. The predicted gp160 sequences
from these resistant isolates were compared to sequences from the
resistant R14 clone and from sensitive viruses. No consistent pattern
was discernible among the gp120 and, speciﬁcally, the V3 sequences
of these various viruses (Fig. 3A and B and data not shown). Thus, the
uncloned D101.12 isolate had all four resistance-associated V3
substitutions (K305R, H308P, A316V and G321E), but while the ﬁrst
two changes were ﬁxed, the other two were unstable. And, as noted
above, the R14 clone contained only the H308P change. Finally, the
reversion culture isolates consistently retained two of the four
resistance-associated V3 changes (K305R and A316V), but the
G321E change was consistently absent (i.e., it had reverted to the
cognate parental sequence, 321G). Of note is that the resistance-
relevant proline at residue 308was absent from the reversion isolates,
and although a change arose at this position, it was not to the
dominant parental histidine, but to a new amino acid, threonine (i.e.,
P308T). Other changes were also evident at V3 positions adjacent to
the ﬁrst two established resistance-associated substitutions, although
only the second of those changes (I309R) had become stabilized by
passage 19. There was also a new substitution (F317I) in the
D101.12R19 virus, located adjacent to the third of the resistance-
associated V3 changes, A316V (Fig. 3B).
Two genetic patterns are present in the D101.12 gp41 subunit
The above sequence analyses imply that the determinants for the
full resistance of D101.12 and related viruses do not lie solely within
gp120. We therefore assessed whether a common genetic determi-
nant of resistance could be found in the gp41 subunit, by sequencingand examining 13 env genes cloned from D101.12. Approximately
half (5/13) of the D101.12 clones contained all four of the resistance-
associated V3 changes, but others possessed only three (3/13), two
(4/13), or one of them (1/13); the H308P change was, however,
invariably present in all the D101.12 clones (Fig. 3A and B). Two
clearly distinct patterns of gp41 sequenceswere apparent: A valine to
methionine substitution at position 535 of the gp41 ectodomain
(V535M) was present in all resistant isolates and clones, but it was
accompanied by either a single G514V change in the FP (Pattern I, 3/
13 clones, Fig. 3C) or two changes, M518V and F519L (Pattern II, 10/
13 clones, Fig. 3D). The Pattern I change adds a bulky hydrophobic
side-chain (G514V), whereas the other FP changes involve semi-
conservative substitutions. Of note is that, in each case, one of the
changes results in the introduction of a C-β branched amino acid
(Val), just as arises in the resistant D1/85.16 virus (Anastassopoulou
et al., 2009). A valine residue is also present at position 518 in 6 of 6
CC101.19 clones (Fig. 3C), although resistance is conferred to this
virus by the four changes in V3 (Kuhmann et al., 2004).
The corresponding V3 sequence pattern of the D101.12 clones
was complex. Among the three clones with gp41 sequence Pattern I,
one (R14) possessed only the H308P change, one had the K305R and
H308P substitutions, while the third, λ60, harbored all four V3
changes (Fig. 3A). Outside of V3, all three Pattern I clones had lost a
potential N-linked glycosylation site in the V4 region as a result of an
N406K substitution (data not shown). However, themajority (10/13)
of the D101.12 clones were of gp41 Pattern II (Fig. 3D), with the
H308P change being the only common feature among their V3 and
gp120 sequences (Fig. 3B and data not shown). Most Pattern II clones
(4/13) contained all four V3 substitutions, three had three changes
(although not consistently in the same combination), while another
three possessed the K305R and H308P changes (Fig. 3B). Among the
Pattern II clones, 5/13 contained the N406K change in V4 (data not
shown).
Clearly, the genetics of VCV resistance are complex for the D101.12
isolate. Two distinct genetic lineages are apparent in gp41, together
with a minimum of one (H308P), and up to all four, of the resistance-
associated mutations in the gp120 V3 region.
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Fig. 2. The D101.12 isolate is resistant to VCV and has a stable phenotype. (A) D101.12
and D1/85.16 were ﬁrst tested for VCV sensitivity alongside their respective parental
viruses, CC101.6 and CC1/85, in a PBMC-based HIV-1 replication assay. The cultures
were infected with each isolate in the presence of the indicated VCV concentration, and
p24 production was measured after 7 days. The data points represent the means of two
independent experiments ± SEM. (B) The VCV-resistant isolate D101.12 was then
cultured for 19 weeks in PBMC from two or three random blood donors, in the absence
of VCV. Viruses from this reversion culture were tested for VCV sensitivity. The
sensitivity proﬁles of representative viruses D101.12R7, D101.12R8, D101.12R10, and
D101.12R19 (from weekly passages 7, 8, 10, and 19, respectively) after 7 days are
shown in comparison to D101.12 and CC101.6. The values shown are the means of at
least three independent experiments ± SEM.
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both gp41 and gp120
The fully resistant R14 clone contains the H308P change in V3, but
no other changes in this region, together with the Pattern I gp41
substitutions, V535M + G514V (Fig. 3). To assess the relative
contributions of the changes in the two Env subunits, we ﬁrst
interchanged the gp120 and gp41 components from the R14 clone
and the parental clone CC1/85 cl.6 (= S). Hence the gp120 component
of the resulting R14/S chimera is derived from R14, the gp41
component from S (Table 1). The R14/S virus was replication-
competent in PBMC with titers of 105 TCID50/mL on day 7 post-
infection (p24 production, 1–4 ng/mL). When VCV resistance was
determined in a PBMC infection–inhibition assay, it was found not to
track with the source of gp120. Thus, the R14/S chimera was only
weakly resistant to VCV, which is consistent with its possession of theH308P change in V3 (Fig. 4A). Overall, R14/S behaved more like the
sensitive clone, S, than the resistant clone, R14. The weak resistance of
the R14/S chimera, which is attributable to the H308P change, is
mainly manifested by the small (~6%), but consistent, level of
replication that occurs at VCV concentrations as high as 5 μM
(MPI = 94 for R14/S and 100 for S; Fig. 4A and Table 2). We can
infer from these results that the full resistance of the R14 clone must,
therefore, be attributable to the inﬂuence of the Pattern I gp41
changes, acting in concert with the H308P change in V3.
Site-directed mutagenesis of gp41 residues
To further examine the genetics of resistance of the D101.12
isolate, we introduced the gp41 substitutions highlighted by the
sequence analysis into both the parental, VCV-sensitive clone S and
the weakly resistant R14/S chimera that contains the H308P change in
V3. Both single residue and combination changes corresponding to
gp41 Patterns I and II were made in these viruses, which were tested
for VCV sensitivity in PBMC in comparison to clones S, R14 and R14/S
(Fig. 4). Similar results were obtained when AD101 was used instead
of VCV (data not shown).
The V535M substitution is common to all D101.12 isolates and
clones, irrespective of which gp41 sequence pattern was present
(Fig. 3C and D). Introducing this change alone into the parental clone S
had no notable effect on the VCV infection–inhibition curve and the
resulting MPI and IC50 values (Fig. 4B and Table 2). The same V535M
change in the R14/S chimera created a virus, R14/S+(V535M), with a
slightly higher IC50 value (0.45 nM vs. 0.21 nM) but with an unchanged
MPI (93 vs. 94) (Fig. 4B and Table 2). Having a methionine at position
535 of the gp41 ectodomainwhen V3-residue 308 is a proline therefore
modestly increases the IC50, but without affecting the incomplete
inhibition plateau that stems from the presence of the proline.
Introducing the two Pattern I gp41 changes (G514V+ V535M) into
the R14/S chimera that also harbors the H308P substitution mimicked
the fully resistant phenotype of clone R14 (Fig. 4C). These two gp41
mutations are, however, necessary, but not sufﬁcient, to confer
resistance, since their insertion into the sensitive clone S resulted in
only a partially resistant virus; hence, the MPI value of the engineered
S+(G514V, V535M) mutant was reduced from 100 to 73 (Fig. 4C and
Table 2). When only the G514V change was made in the S clone, the
VCV dose–response curve was shifted to the left, resulting in a 6-fold
lower IC50 value (0.13 nM vs. 0.73 nM, Table 2). Hence, the S+(G514V)
virus, like S+(V535M), remained VCV sensitive (Fig. 4B and C). When
the same G514V mutation was engineered in the context of the H308P
change, the resulting R14/S+(G514V) virus was difﬁcult to grow; it
replicated sufﬁciently for its response to VCV to be properly
quantiﬁable in only 3/11 of PBMC-based infection–inhibition assays.
However, this virus also was partially VCV resistant, with an MPI value
of 72 (Fig. 4C and Table 2). The further addition of the V535M change to
R14/S, creating the R14/S+(G514V, V535M) mutant made the virus
replication-competent and rendered it fully resistant (Fig. 4C and
Table 2). Thus, the VCV dose–response curve for R14/S+(G514V,
V535M) was almost completely coincident with that of the reference,
VCV-resistant clone R14. Of note is that both curves had complex
shapes. There was an inhibition peak of ~30–40% at low VCV
concentrations (~0.3–2 nM) but a lesser effect at higher concentrations
with the curves leveling off at ~18–20% inhibition at 5 μM of VCV
(Fig. 4C). We have previously described, and modeled, dose–response
curves with this unusual conﬁguration for viruses for which VCV
resistance is due to FP changes (Anastassopoulou et al., 2009).
As noted above, most D101.12 clones were of gp41 sequence
Pattern II, for which the important changes were M518V and F519L in
the FP, together with the downstream V535M substitution (Fig. 3D).
The introduction of the two FP changes into the parental S clone
created a VCV-sensitive virus, S+(M518V, F519L) (Fig. 4D). The dose–
response curve for this virus was shifted to the left, similarly to the
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Fig. 3. V3 and N-terminal gp41 sequence alignments from VCV-sensitive and VCV-resistant viruses. (A and B) The 35 residues from the gp120 V3 region and (C and D) the ﬁrst 29
amino acid residues from the gp41 N-terminus are shown for seven clones from the parental, VCV-sensitive virus CC1/85, 13 clones (3 and 10 of gp41 Patterns I and II, respectively)
and four isolates based on the VCV-resistant isolate D101.12 as well as six clones from the AD101- and VCV-resistant isolate CC101.19. Ten clones (one of gp41 Pattern I and nine of
gp41 Pattern II, two of which contained only the H308P substitution) were excluded from the analysis since they contained premature stop codons and were presumably non-
infectious (data not shown). The sequences are recorded relative to that of CC1/85 cl.16 (top line), with dots indicating amino acid sequence identity. Substitutions that inﬂuence
resistance, as discussed in themain text, are highlighted in bold. Among the seven parental clones, CC1/85 cl.16 (= S, GenBank accession no. AY 357338) is themost closely related to
D101.12 cl.14 (= R14); these two clones, which were used for subsequent genetic studies, are boxed. Amino acid numbering is based on HXB2 Env, with the ﬁrst residue of V3 at
position 296 and of gp41 at position 512.
51C.G. Anastassopoulou et al. / Virology 413 (2011) 47–59effect of the Pattern I FP change creating the S+(G514V) virus (IC50=
0.13 nM for both viruses) (Fig. 4C and D, and Table 2). The further
addition of V535M to make the triple mutant, S+(M518V, F519L,
V535M), created a virus that was weakly resistant; its dose–response
curve was shifted rightward (IC50 = 0.71 nM), but with an MPI of 92
compared to 73 for S+(G514V, V535M) (Fig. 4C and D, and Table 2).
Thus, when the gp41 Pattern I changes (G514V + V535M) are
combined in the context of the parental clone S (i.e. in the absence of
H308P), they have a more pronounced effect than the combined
Pattern II changes (M518V, F519L, V535M), as manifested by the
lower MPI value (Fig. 4C and D, and Table 2).
Introducing the Pattern II gp41 changes into the R14/S chimera,
and hence in the context of the H308P change in V3, created a virus,
R14/S+(M518V, F519L, V535M), that was only partially resistant. The
inhibition plateau of this triple mutant was ~1.5-fold higher than that
of the double mutant R14/S+(M518V, F519L) virus (MPI = 82 vs. 53,respectively) (Fig. 4D and Table 2). Hence when a proline is present at
position 308, the V535M substitution reinforces the effects of the
Pattern I change in the FP (G514V), but not the Pattern II changes
(M518V, F519L) (Fig. 4C and D, and Table 2).
Manifestation of VCV resistance is cell type-dependent
Resistance to small molecule CCR5 inhibitors is known to varywith
the cell type (Anastassopoulou et al., 2009; Ogert et al., 2008; Pugach
et al., 2007;Westby et al., 2007). To further characterize the resistance
proﬁles of the engineered infectious clones, we tested them for their
VCV sensitivity in TZM-bl cells (Fig. 5). The MPI reﬂects the relative
ability of the virus to use the inhibitor-bound and the inhibitor-free
forms of the co-receptor for entry; the higher the MPI value, the less
efﬁciently a resistant virus uses the inhibitor–CCR5 complex (Pugach
et al., 2007; Westby et al., 2007). As in the PBMC assay, the
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Fig. 4. VCV resistance maps to both gp41 and gp120. The engineered R14/S chimera and mutant viruses were tested for VCV sensitivity in a PBMC-based, multi-cycle replication assay
with p24 productionmeasured after 7 days. For comparison, the parental inhibitor-sensitive clone S and the VCV-resistant clone R14were also tested in the same experiments. For clarity,
the dose–response curves are shown in separate panels for the R14/S chimera (A), and the mutants harboring either the V535M change only (B), or the complete set of gp41 changes of
Pattern I (C), or Pattern II (D). VCV inhibition curves were created by ﬁtting the model function, Q=(1-(1-(C/(Kdi+C))+w *(C/(4.3*Kdi+C))))*100%, to the average PBMC data, since
sigmoid dose–response curves did not ﬁt the data for viruses that were resistant to various degrees in these cells. The results shown are the average of 3–11 independent experiments,
with the error bars indicating the SEM.
52 C.G. Anastassopoulou et al. / Virology 413 (2011) 47–59replication-competent mutants were tested for VCV sensitivity in
comparison to the reference parental clone S, the weakly resistant
R14/S chimera, and the VCV-resistant clone R14 (Fig. 5). Similar
results were obtained when AD101 was used instead of VCV (data not
shown).
Themodel functionwas ﬁtted to the average TZM-bl cell inhibition
data to determine MPI and IC50 values (Fig. 5 and Table 2). The VCV
sensitivity proﬁles of the parental clone S and the R14/S chimera were
similar to those seen for each virus in the PBMC assay (Fig. 4A). The
MPI values were 99 and 95, respectively, but the IC50 value (9.6 nM)
for R14/S was about half that for S (21 nM) (Fig. 5A and Table 2). The
VCV-resistant R14 virus, in contrast, had a reduced MPI value of 79,
and a leftward shift in the dose–response curve that lowered the IC50
to 3.7 nM (Fig. 5A and Table 2).
Introducing the V535M substitution, which is common to both
gp41 patterns, into the parental clone S had no effect on the VCV
infection–inhibition curve and the resulting MPI and IC50 values
(Fig. 5B and Table 2). In contrast, making the same V535M change in
R14/S (i.e., in the context of the H308P change in V3) caused arightward shift of the dose–response curve, just as it did in PBMC
(Fig. 4B), and an ~3-fold increased IC50 (30 nM vs. 9.6 nM for R14/S)
(Fig. 5B and Table 2).
The fully resistant phenotype of clone R14 was again mimicked by
the introduction of the two Pattern I gp41 changes (G514V+V535M)
into the R14/S chimera (Fig. 5C). The resulting, leftward-shifted dose–
response curve yielded MPI and IC50 values that were both reduced
compared to the R14/S chimera (Table 2). When the same two
changes were made in the parental clone S, the dose–response curve
was again shifted leftward, but not downward, yielding an IC50 value
~4-fold lower than for S (5.2 nM vs. 21 nM, respectively) (Fig. 5C and
Table 2).
The R14/S+(G514V) singlemutant was consistently able to replicate
in TZM-bl cells, which contrasts with its replication incompetence in
PBMC (data not shown). The VCV dose–response curve for R14/S+
(G514V) was very similar to those of R14 and R14/S+(G514V, V535M),
as were the corresponding MPI (85 vs. 79 and 83, respectively) and IC50
values (3.4 nMvs. 3.7 and 2.4 nM, respectively) (Fig. 5C and Table 2). The
S+(G514V) single mutant and the S+(G514V, V535M) double mutant
Table 2
VCV inhibition of HIV-1 replication in PBMC and TZM-bl cellsa.
PBMC TZM-bl cells
Virus MPI IC50 (nM) MPI IC50 (nM) VCV phenotypeb
S 100 0.73 99 21 Sensitive
S+(G514V) 100 0.13 97 4.4 Sensitive
S+(G514V, V535M) 73 0.84 96 5.2 Partially resistant
S+(M518V, F519L) 99 0.13 100 2.2 Sensitive
S+(M518V, F519L, V535M) 92 0.71 98 4.1 Weakly resistant
S+(V535M) 100 0.69 99 25 Sensitive
R14 42 NA 79 3.7 Resistant
R14/S 94 0.21 95 9.6 Weakly resistant
R14/S+(G514V) 72 0.25 85 3.4 Partially resistant
R14/S+(G514V, V535M) 41 NA 83 2.4 Resistant
R14/S+(M518V, F519L) 53 0.82 93 1.0 Partially resistant
R14/S+(M518V, F519L, V535M) 82 0.19 91 1.9 Partially resistant
R14/S+(V535M) 93 0.45 96 30 Weakly resistant
MPI, maximum percent inhibition; NA, not applicable.
a The model function for inhibition, Q=(1-(1-(C/(Kdi+C))+w *(C/(4.3*Kdi+C))))*100%, was ﬁtted to the average PBMC and TZM-bl data (see Figs. 4 and 5) to determine MPI
and IC50 values (see Materials andmethods and Results; R2 values are given in Table 3). The IC50 is the VCV concentration (C) that yields 50% inhibition (Q). The IC50 therefore applies
only when MPIN50%, and it can be substantially larger than the VCV concentration that would inhibit to an extent equal to 50% of the MPI value. MPI is deﬁned as the upper plateau
for sigmoid curves, or as the maximum inhibition value for peaked curves.
b Viruses with MPI values in the range 90–95 for VCV inhibition in PBMC are considered to be weakly resistant, 50–90 partially resistant, b50 fully resistant. The fully resistant
viruses, according to this criterion, are highlighted in bold.
53C.G. Anastassopoulou et al. / Virology 413 (2011) 47–59had similar MPI and IC50 values (Fig. 5C and Table 2). In both cases, the
virus was almost fully inhibited (MPI valuesN96), but with IC50 values
~4-fold lower than for S (Table 2).
Introducing the Pattern II gp41 changes into both S and the R14/S
chimera also caused leftward shifts in dose–response curves (Fig. 5D).
The S+(M518V, F519L) double mutant and the S+(M518V,
F519L+V535M) triple mutant had similar MPI (N98) and IC50 (2.2
nM and 4.1 nM, respectively) values, the latter being ~7-fold lower
than for S (Fig. 5D and Table 2).When the same changesweremade in
the R14/S chimera, the leftward shifts were now accompanied by
lower inhibition plateaus (Fig. 5D). The resulting MPI values of 93 and
91 for R14/S+(M518V, F519L) and R14/S+(M518V, F519L, V535M)
were comparable to that of R14/S, but the corresponding IC50 values of
1.0 nM and 1.9 nM were lower (Table 2). The reductions in the IC50
values for the R14/S mutants are therefore attributable to the
combination of the Pattern II gp41 changes, while the reduced MPI
values arise from the presence of Pro-308 in the V3 region.
The engineered mutant viruses that are VCV-resistant in PBMC
therefore display the non-competitive resistance indicator that is a
feature of the TZM-bl cell assay; i.e. MPI values signiﬁcantly below
100%. However, the mutants also have lower IC50 values than the
parental virus. This property is not just atypical for a resistant virus; it
is apparently paradoxical, as discussed previously for the D1/85.16
isolate (Anastassopoulou et al., 2009).
To gain a better understanding of how VCV resistance is inﬂuenced
by sequence variation in only the FP (e.g., as in isolate D1/85.16),
compared to changes in both gp120 and gp41 (e.g., as in isolate
D101.12), we tested uncloned isolates for VCV sensitivity in the same
TZM-bl cell assay (Fig. 5E). Similar results were obtainedwhen AD101
was used instead of VCV (data not shown). The input CC1/85 and
CC101.6 isolates had comparable MPI values of 91 and 90, respec-
tively, although CC101.6, which is weakly resistant in PBMC (Fig. 2A),
had a slightly lower IC50 value (11 nM, compared to 18 nM). The two
isolates that are fully resistant in PBMC (Fig. 2A) had unusual VCV
dose–response curves in TZM-bl cells. Thus, D101.12 was only
minimally inhibited (0–5%) by VCV concentrations up to ~200 nM,
while infection by the D1/85.16 isolate was modestly but consistently
enhanced (~25%) at very low concentrations (up to ~0.3 nM). The
lower MPI value for D101.12 compared to D1/85.16 (24 vs. 51,
respectively) implies that it uses the inhibitor–CCR5 complex more
efﬁciently. For D101.12, this outcome arises from the cooperative
action of sequence change in both gp120 and gp41, whereas for D1/85.16 the three substitutions in the FP have the same effect, although
to a lesser extent.
Sensitivity to other inhibitors
All the test viruses had been carefully titrated in each cell system,
to allow nominally equivalent titers (100 TCID50 per well of a 96-well
plate) to be used in subsequent inhibitor-sensitivity experiments.
Despite these precautions, we considered it possible that titer
variations could inﬂuence the resulting IC50 values for the different
viruses, and hence perhaps the diagnosis of resistance. To gauge the
magnitude of any such variations, we tested zidovudine (AZT), an
antiviral drug that does not target Env, under the same conditions. The
similar AZT-sensitivity proﬁles of the test viruses contrasts markedly
with the differences seen using VCV in the same experiment (SI
Fig. 1A and B). We observed similar results using the broadly
neutralizing monoclonal antibody 2F5, which inhibits virus entry at
a later stage than VCV (SI Fig. 1C). The observed differences in VCV
IC50 values are, therefore, not merely due to virus titer variations. Of
note, however, is that viruses harboring the gp41 Pattern I changes,
G514V and V535M, were more sensitive to the fusion inhibitor
enfuvirtide (T20) than other viruses from this lineage, irrespective
whether the H308P change in gp120 was present or not (SI Fig. 1D).
Future studies will focus on understanding the latter observation.
VCV resistance is not due to a switch in co-receptor usage
To determine whether any of the engineered resistant variants of
D101.12 had acquired the ability to use CXCR4 for entry, we assessed
their replication in PBMC from a CCR5-Δ32/Δ32 homozygous donor,
and their sensitivity to the CXCR4-speciﬁc small molecule inhibitor
AMD3465. In contrast to the reference X4 and R5X4 viruses (NL4-3
and CC2/86, respectively), the fully resistant clone R14 and the
engineered resistant virus R14/S+(G514V, V535M) did not produce
detectable amounts of p24 in CCR5-Δ32/Δ32 PBMC. Moreover, their
replication in normal donor PBMC was insensitive to 500 nM
AMD3465 (Fig. 6). The extent of replication with AMD3465, relative
to its absence, did not differ between the VCV-sensitive viruses (S and
R14/S) and -resistant viruses (R14 and R14/S+(G514V, V535M)),
Mann–Whitney U two-tailed test for pooled replicates of each
category, p=1.0. Similar results were obtained using the other
D101.12 variants described above (data not shown).
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Fig. 5. Determinants of VCV resistance in a TZM-bl cell-based assay. The same clonal viruses studied in PBMC were assessed for VCV sensitivity in TZM-bl cells with a luciferase
reporter gene endpoint. For comparison, the parental inhibitor-sensitive clone S, the engineered R14/S chimera, and the VCV-resistant clone R14 were also tested. For clarity, the
dose–response curves are shown in separate panels for the R14/S chimera (A), and for themutants containing either the V535M change only (B), or the complete set of gp41 changes
of Pattern I (C) or Pattern II (D). The uncloned isolates were also studied (E). For consistency, VCV inhibition curves were again created by ﬁtting the model function, Q=(1-(1-(C/
(Kdi+C))+w *(C/(4.3*Kdi+C))))*100%, to the average TZM-bl data. The results shown are the average of 3 independent experiments for the mutant clones (panels A–D) and 2–6
experiments for the isolates (panel E), with the error bars indicating the SEM.
54 C.G. Anastassopoulou et al. / Virology 413 (2011) 47–59The VCV-resistant viruses were also tested in TZM-bl cells in the
presence and absence of AMD3465 (500nM). The incomplete inhibition
plateaus described above (Fig. 5 and Table 2) were unaffected by the
presence of theCXCR4-speciﬁc inhibitor (data not shown).We conclude
that the VCV resistance of D101.12 and the engineered mutants is not
due to a switch to CXCR4 usage in PBMC or TZM-bl cells.Modeling VCV inhibition and resistance
We applied a previously developed model to analyze the
inhibitory effect of VCV on HIV-1 infection of PBMC and TZM-bl
cells (Anastassopoulou et al., 2009). The model is a quantitative
formulation of the hypothesis that two distinct forms of CCR5 with
Fig. 6. VCV resistance does not involve switching to CXCR4 use. Replication of the VCV-sensitive clone S, the weakly resistant R14/S chimera, and the VCV-resistant viruses R14 and
R14/S+(G514V, V535M) was determined in PBMC from CCR5 wild-type and CCR5-Δ32/Δ32 homozygous donors in the presence and absence of the CXCR4-speciﬁc inhibitor
AMD3465 (500 nM). The reference viruses NL4-3 (X4) and CC2/86 (R5X4) were included for comparison. HIV-1 replication was quantiﬁed by measuring p24 production on day 14
post-infection.
55C.G. Anastassopoulou et al. / Virology 413 (2011) 47–59high or low afﬁnity for VCV exist on the surfaces of different cell types
in varying proportions. The inhibition of viral infectivity, Q, is a
function of the concentration, C, of VCV according to the equation
Q = 1− 1− C = Kdi + Cð Þð Þ + w C = Kde + Cð Þð Þ
  100%
where Kdi is the postulated dissociation constant for the binding of
VCV that blocks viral usage of CCR5 and Kde, correspondingly, for any
such binding that allows it. Thew term reﬂects the relative abundance
of the CCR5 form that can bind VCV with low afﬁnity, and also the
efﬁcacy with which a resistant virus can use that CCR5 form as a VCV
complex. According to themodel, a VCV-sensitive virusmay be able to
use both the high- and low-afﬁnity forms of inhibitor-free CCR5 to
various extents, whereas a resistant virus has a preference for the
unoccupied high-afﬁnity form of the receptor and for the occupied
low-afﬁnity receptor (Anastassopoulou et al., 2009).
The resistant viruswith three FP changes (D1/85.16 cl.23; i.e., clone R)
that we previously described was characterized by wN0 (large values on
PBMC and smaller on TZM-bl cells), and its Kdi value on TZM-bl cells was
lower than those for VCV-sensitive viruses (Anastassopoulou et al., 2009).
To assess whether the various engineered viruses described above
behaved similarly to clone R, and to explore which amino acid
substitutions segregated with the various aspects of the resistance
phenotype, wemodeled data for VCV inhibition of infection of PBMC and
TZM-bl cells.
We lacked a sufﬁcient number of data points to determine all three
parameters (w, Kdi and Kde) simultaneously. We therefore optimized
the ratio of Kde/Kdi to 4.3 based on data for the reference resistant
virus, the R14 clone. In our previous study of other mutants, the
optimal Kde/Kdi ratio was 22 (Anastassopoulou et al., 2009). Here, the
lower ratio of 4.3 gave at least as good ﬁts to the experimental data for
all the resistant and sensitive viruses as it did for R14. The implication
is that the resistant viruses being analyzed here discriminate less than
the previously studied ones between the high- and low-VCV afﬁnity
forms of CCR5. However, they do not use the VCV–CCR5 complexes
less efﬁciently since their w values were, generally, not lower. The
resulting nonlinear regression ﬁts all yielded R2 values N0.75 and in all
but three cases N0.96 (Table 3). The modeling results for the viruses S
and R14 resembled what we found previously for S and the resistant
virus S+3FP (Anastassopoulou et al., 2009). Thus for S,w=0while for
R14, w was substantial for both cell types but larger for PBMC than
TZM-bl cells.
The highw value for R14 on TZM-bl cells, which indicates efﬁcient use
of the VCV–CCR5 complex, is largely reproduced for the R14/S+(G514V)
and R14/S+(G514V, V535M) mutants and partly so for R14/S+(M518V,
F519L, V535M) and R14/S+(M518V, F519L). The paradoxical reduction
in the inhibitory Kd value for resistant viruses on TZM-bl cells (i.e., the
leftward shift in the VCV dose–response curve, Fig. 5C and D) could be
partly attributable to mutations other than those responsible for raisingw. Thus, one ormore of the three FP changes (G514V,M518V, F519L), but
not V535M (Fig. 5B), may contribute to this particular phenotype of the
resistant viruses. We will address this point further in a future report on
the contribution of the individual FP changes to various aspects of VCV
resistance.
Overall, the VCV resistance proﬁle for the R14 clone is complex.
Thus, reasonable data ﬁts for VCV inhibition of R14 infection of PBMC
can only be obtained if we factor in some afﬁnity heterogeneity
among the various forms of CCR5. The mutants that apparently use
VCV–CCR5 complexes on PBMC most efﬁciently (i.e. with a high
w value) were R14/S+(G514V, V535M) and R14/S+(M518V, F519L).
The G514V and V535M changes generate robust resistance on both
cell types when they are introduced together into the S clone, as does
the single G514V change when it is made in the context of R14/S but
not S (Table 3). The V535M change enhances the usage of VCV–CCR5
complexes for viruses with gp41–Pattern I sequences, but when it was
added to the Pattern II-derived virus R14/S+(M518V, F519L) it
reduced the w value from 0.57 to 0.18. The various gp41 mutations
may therefore interact to enable the virus to take different escape
routes.
The data we havemodeled here represent averages derived from 3
to 11 experiments for 13 different viruses (1690 data points), each
experiment using a mixture of PBMC from two individuals. VCV
inhibition curves sometimes differed from experiment to experiment,
in that the curves were sometimes fairly ﬂat, but in other cases with
an inhibition maximum in the middle or a plateau to the right (SI
Fig. 2A and B). Indeed, on occasion, we even saw strong enhancement
of infection at the highest VCV concentrations (SI Fig. 2C). These types
of proﬁle were reproduced when the two fully resistant viruses, R14
and R14/S+(G514V, V535M), were included in the same eight
experiments, each performed using PBMC from the same donor
pair. When we modeled the data set, derived from a single pair of
PBMC donors, that displayed the most pronounced VCV-mediated
infectivity enhancement, we obtained w values of 1.5±0.11 for R14
and 1.6±0.051 for R14/S+(G514V, V535M) (R2=0.81 and 0.87,
respectively). These w values are higher than ones based on the
average inhibition seen in all the experiments taken together. They
indicate the presence of particularly prevalent VCV–CCR5 complexes
that could be used by these viruses. Taken together, these observa-
tions suggest that the forms of CCR5 on the cell surface vary from
donor to donor.
Discussion
In this study, we investigated the genetic pathway involved in the
resistance of theHIV-1 isolate D101.12 to VCV and other small molecule
CCR5 inhibitors. Resistance to this class of compound is typically caused
by changes in the gp120 V3 region (Baba et al., 2007; Kuhmann et al.,
2004; Laakso et al., 2007; Ogert et al., 2010; Ogert et al., 2008; Tsibris
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56 C.G. Anastassopoulou et al. / Virology 413 (2011) 47–59et al., 2008; Westby et al., 2007). Although derived from a common
parent, CC1/85, two resistant viruses that we previously described,
CC101.19 and D1/85.16, followed different genetic pathways to reach
the same phenotypic endpoint: CC101.19 acquired four substitutions
(K305R, H308P, A316V and G321E) in the V3 region (Kuhmann et al.,
2004), while the key determinants of resistance in D1/85.16were three
changes in the gp41 FP (G516V, M518V and F519I) (Anastassopoulou
et al., 2009). Both resistant variants acquired the ability to use the
VCV–CCR5 complex for entry (Anastassopoulou et al., 2009; Kuhmann
et al., 2004; Pugach et al., 2007; Trkola et al., 2002); they do, however,
differ in their dependence on the CCR5 N-terminus and their exposure
of regions of gp120 associated with the CCR5-binding site, with the FP
changes having a much lesser effect on the overall topology of the Env
complex (Berro et al., 2009).
The D101.12 isolate arose from the weakly resistant CC101.6 virus
that harbors the critical H308P change and, like D1/85.16, it is
completely resistant to VCV in PBMC assays. Both D1/85.16 and
D101.12 have highly stable phenotypes, in that they retain their
resistance when cultured in PBMC for multiple passages in the absence
of the inhibitor (Anastassopoulou et al., 2009). Hence these viruses
resemble CC101.19 in being ﬁt, well adapted to PBMC and not requiring
the selecting compound to replicate efﬁciently (Anastassopoulou et al.,
2007).
The fully resistant D101.12 clone R14 contains an H308P
substitution in V3 that confers modest VCV resistance, but lacks the
three later-arising, resistance-associated changes in V3 that are often
needed for full resistance (Kuhmann et al., 2004; Marozsan et al.,
2005). Clones derived from the D101.12 isolate and from its reversion
culture also did not consistently possess all four of the V3 resistance-
associated changes. Approximately half of the D101.12 clones (5/13)
contained all four V3 changes, the rest possessing fewer, with only
H308P being invariably present. We therefore considered it possible
that additional mutations elsewhere in env could be contributing to
the full VCV resistance of the D101.12 isolate. The R14 clone is not
representative of the D101.12 isolate fromwhich it was derived, but it
provided an opportunity to study the interactions between V3 and
other Env sequences that arise during resistance development. Our
hypothesis was that gp41 changes contributed to the resistance of the
D101.12 isolate, but we could not easily test this idea using a clone
that harbored additional V3 changes. Hence we used the R14 clone,
which contains only the H308P change in V3 and yet is fully VCV-
resistant, in our domain swapping andmutagenesis strategies.We did
this both to study how R14 had become resistant and to gain more
general insights into the interplay between gp120 and gp41.
An N406K substitution that results in the deletion of a potential
N-linked glycosylation site was present in the gp120 V4 region in
more than half of the D101.12 clones (8/13), including clone R14 as
previously described (Marozsan et al., 2005). The loss of a glycosyl-
ation site in the C-terminal part of V4 from the JR-CSF isolate has been
associated with the more efﬁcient use of an N-terminally-deleted
CCR5 mutant, suggesting that sequence changes in this area can
inﬂuence Env-CCR5 interactions (Platt et al., 2005). Other changes in
V4, D407G and the loss of a glycosylation site at residue 386, have
been reported to modulate the magnitude of clinical resistance to
MVC that is conferred principally by V3 changes (Tilton et al., 2010).
We did not, however, further study the N406K change here, because it
was not consistently present in all the D101.12 clones and it was not
associated with the number or identity of the changes in V3 (data not
shown). Inspection of the location of the N406K change on the gp120
core structure does not reveal any clues as to how it might affect the
co-receptor interactions of the native Env trimer (data not shown).
We used the R14 clone to study the interplay between the
sequence changes in V3 and gp41 that conferred full resistance on the
D101.12 isolate. The two separate gp41 sequence patterns both
involved the substitution of hydrophobic amino acids in the FP
(G514V, M518V, F519L), together with an additional V535M change.
57C.G. Anastassopoulou et al. / Virology 413 (2011) 47–59The gp41 sequence variations were accompanied by a minimum of
one (H308P), but up to all four, of the resistance-associated
substitutions in V3. The gp41 Pattern I changes were G514V +
V535M, while Pattern II was M518V + F519L + V535M. Studies with
chimeric viruses in which the gp120 and gp41 subunits of VCV-
sensitive and -resistant viruses were exchanged showed that
resistance did not track with the source of gp120, but was, instead,
conferred by the cooperative action of changes in both gp120 and
gp41. Of note is that the majority of D101.12 clones of both gp41
patterns simultaneously harbored three, if not all four, V3 resistance-
associated changes; changes in both Env subunits appear to
contribute to the survival of these viruses under the selection
pressure of VCV. These changes persist even when VCV is absent,
presumably because they do not carry an associated ﬁtness cost. A
simian–human immunodeﬁciency virus selected in macaques for
resistance to PSC-RANTES, a CCR5 inhibitor based on one of its
chemokine ligands, also contains a combination of V3 (K315R) and
gp41 (N640D) changes (Dudley et al., 2009). Clinical resistance to the
small molecule CCR5 inhibitor, aplaviroc, is conferred by V3 changes
although changes elsewhere in gp120 and gp41 modulate their
inﬂuence (Pfaff et al., 2010).
Mutagenesis studies followed by PBMC infection–inhibition assays
showed that individual gp41 amino acid changes generally had a
minor and often context-dependent effect on the resistance pheno-
type. The V535M substitution appears to compensate for the
otherwise replication impairing effect that is created when the
G514V and H308P changes are combined, rather than having a direct
impact on resistance. The two Pattern I gp41 changes conferred full
resistance when they were both present in a virus that also contained
the H308P substitution in V3 (e.g., as in clone R14), but when H308P
was absent they created only a partially resistant virus. Hence the
V535M + G514V substitutions are necessary, but not sufﬁcient, to
cause VCV resistance, while neither change has much, if any effect,
when made in isolation. The increased T20 sensitivity of viruses
bearing the gp41 Pattern I sequence combination compared to other
viruses from this lineage, irrespective of the presence or absence of
the H308P change in gp120, provides clues to how these gp41 changes
may be acting. Follow-up studies will be designed accordingly.
Resistance to a novel entry inhibitor, PF-68742, is associatedwith a
G514R change in the FP, together with additional changes in gp41 that
probably affect how this subunit interacts with gp120 (Murray et al.,
2010). The FP residue involved is the same one that changes in the
VCV escape mutants of gp41 Pattern I, although the substitution
associated with PF-68742 resistance involves the introduction of a
positively charged residue (G514R vs. G514V). Although PF-68742
and VCV have different targets, the Env proteins and CCR5
respectively, there seem to be similarities in the process by which
HIV-1 escapes from the selection pressure they impose.
Among D101.12 clones, Pattern II gp41 changes were much more
common than Pattern I. The two Pattern II changes, M518V+ F519L in
the FP, did not confer resistancewhen introduced into a virus lacking the
H308P change, and the further introduction of the V535M change to
create the triple mutant produced only a weakly resistant virus. Indeed,
in a virus lacking theH308P change, the Pattern II changes had less of an
effect than Pattern I. As with the Pattern I changes, the resistance-
conferring effect of the Pattern II substitutions was only manifested in
the context of a virus containing the H308P substitution in V3, although
the overall effect was to confer partial and not full resistance.
We, and others, have reported previously that the manifestation of
CCR5 inhibitor resistance is dependent on the cell type in which the
assays are performed. In engineered cell lines, resistance is usually
detected not by a rightward shift in a dose–response curve and a
concomitant rise in the IC50 value, but by a lower plateau that is
quantiﬁedby a reduction in theMPI value (Anastassopoulouet al., 2009;
Ogert et al., 2008; Pugach et al., 2007;Westby et al., 2007).We therefore
repeated the infection–inhibition assays for the various chimeric andmutant clones, using TZM-bl cells. In general, the relationships between
genetic changes and the manifestations of resistance were similar in
TZM-bl cells and PBMC, although somedifferenceswere apparent. Thus,
unlike in PBMC, theV535Mchange is not required to compensate for the
presence of the H308P and G514V changes when the relevant viruses
replicate in TZM-bl cells.Why this is the case remains to be determined.
Various viruses that are VCV-resistant in PBMC had MPI values
signiﬁcantly below 100% in the TZM-bl cell assay, an expected outcome
of experiments in these cells. However, in many cases, the mutants also
have lower IC50 values than the parental virus. This apparently
paradoxical property of a resistant virus is somethingwe have observed
and discussed previously (Anastassopoulou et al., 2009). By comparing
the properties of various gp41mutant clones of both sequence patterns
that either contained or lacked the H308P change in V3, we found that
the IC50 reductions are attributable to FP changeswhile the reducedMPI
values are driven by the H308P substitution.
The resistance pattern for the R14 virus ismore complex than can be
explained by the equal and interchangeable use of all the VCV-bound
and free forms of CCR5. Our modeling has indicated that multiple forms
of CCR5 with heterogeneous afﬁnities for VCV are present on the cell
surface (Anastassopoulou et al., 2009). The model shows that R14
appears to use VCV–CCR5 complexes strongly (i.e., it has a highw). The
R14/S+(G514V, V535M) mutant that recapitulates the R14 phenotype
also has a comparable w value. However, no mutations in either gp120
or gp41 alone could entirely reproduce the R14 phenotype, although
some of the FP sequence changes were sufﬁcient to have substantial
effects onw. The other phenotypic trait possessed by the resistant virus
is the paradoxical reduction in the inhibitory concentration of VCV that
is primarily seen with TZM-bl cells but is also discernable by modeling
the PBMC data. This property could be recreated by introducing several
different permutations of single, double and triple FPmutations into the
VCV-sensitive, parental virus, S.We suggest that the paradoxical shift to
a lower IC50 is a byproduct of a subset of escape routes that involve
changes in the FP; as noted, this aspect of the phenotype is most
pronounced in TZM-bl and other cell lines that were neither used in the
original selection nor are physiologically relevant targets for infection.
We have proposed that the IC50 reductions are explained by themutant
virus switching to use unoccupied forms of CCR5 for which VCV has a
higher afﬁnity, compared to the forms that the wild type virus can use
(Anastassopoulou et al., 2009). This side effect of the escape phenotype
illustrates that, to the virus, drug efﬁcacy is matter of survival, whereas
drug potency is a matter of convenience.
Cooperative interactions between the subunits are a general
feature of the functional Env trimer (Salzwedel and Berger, 2009).
For some resistant viruses from the D101.12 lineage, the use of VCV–
CCR5 complexes may be facilitated by substitutions in gp41 that work
in concert with at least the H308P change in V3. In the alternative,
more frequently seen and less complex, pathway, multiple changes in
V3 achieve the same effect (i.e., for the fully resistant CC101.19 virus,
H308P is supplemented by the three additional V3 changes)
(Kuhmann et al., 2004). But changes only in the FP can also be both
necessary and sufﬁcient for full resistance, as occurs in D1/85.16
(Anastassopoulou et al., 2009). It remains to be understood how these
different, but inter-related, genetic pathways affect the overall
structure and function of Env in a way that enables it to use VCV–
CCR5 complexes for entry. The impact the resistance-associated
changes have on how the FP functions also remains to be deﬁned,
taking into account current models of its structure (Buzon et al., 2010;
Jaroniec et al., 2005; Qiang et al., 2008; Qiang and Weliky, 2009).
Materials and methods
Reagents
The small molecule CCR5 inhibitors VCV (SCH-D, SCH-417690)
and AD101 (SCH-350581) were provided by Dr. Julie Strizki
58 C.G. Anastassopoulou et al. / Virology 413 (2011) 47–59(Schering-Plough Research Institute), while the small molecule
CXCR4 inhibitor AMD3465 was obtained from Gary Bridger of
AnorMED Inc (now Genzyme Inc).Viruses
The study viruses are listed in Table 1, with their passage history
portrayed graphically in Fig. 1. In brief, D101.12 arose from the weakly
resistant CC101.6 isolate after 12 passages with VCV (Marozsan et al.,
2005). Samples from intermediate stages of this escape culture were
unavailable, so the evolution of env sequence changes in D101.12
during the generation of resistance could not be studied. CC101.6 had
been isolated from the passage 6 culture of the parental CC1/85 isolate
with AD101 (Trkola et al., 2002). The ~4-fold resistance of CC101.6
compared to its parent virus stems largely from an H308P polymor-
phism in the V3 region that presumably allows for improved
exploitation of lower levels of free CCR5 (Kuhmann et al., 2004;
Trkola et al., 2002). Infectious stocks were prepared by transient
transfection of 293T cells with pNL4-3/env proviral plasmids using
Lipofectamine 2000 (Invitrogen) according to the manufacturer's
instructions, and titrated before use as described (Anastassopoulou
et al., 2009; Kuhmann et al., 2004). Env genes were sequenced as
described (Marozsan et al., 2005; Trkola et al., 2002), and alignedwith
MacVector 10.5.1. The sequences have been submitted to GenBank
(accession numbers HQ591389-HQ591416).Construction of chimeric NL4-3/env proviruses
The env gene in the R14/S chimera, which contains gp120 from
VCV-resistant D101.12 cl.14 (= R14) (Marozsan et al., 2005) and
gp41 from parental CC1/85 cl.6 (= S) (Kuhmann et al., 2004), was
constructed using the unique MfeI sites, sequenced, then subcloned
into pNL4-3 to produce chimeric infectious viruses, as previously
described (Anastassopoulou et al., 2009). To introduce mutations into
the gp41 subunit of the S and the R14/S viruses, site-directed
mutagenesis was performed with QuickChange II (Stratagene),
using pBluescript KS(+) plasmids containing EcoRI/XhoI fragments
that were then subcloned into pNL4-3.Infection–inhibition assays
HIV-1 sensitivity to VCV or AD101 was assessed using PBMC from
two or three random blood donors or TZM-bl cells, as previously
described (Anastassopoulou et al., 2009; Ketas et al., 2007; Kuhmann
et al., 2004; Marozsan et al., 2005); the PBMC assay endpoint was p24
production after seven days of infection, whereas with TZM-bl cells,
luciferase expression in relative light units (RLU) was measured after
2 days. The model function for inhibition, Q=(1-(1-(C/
(Kdi+C))+w*(C/(4.3*Kdi+C))))*100% (Anastassopoulou et al.,
2009; Klasse, 2007), was ﬁtted to the average PBMC and TZM-bl
data by nonlinear regression (Prism, Graphpad) (Anastassopoulou et
al., 2009; Klasse, 2007). The model function was ﬁtted by nonlinear
regression (Prism, Graphpad) to determine MPI and IC50 (as deﬁned
in Table 2) as well as Kdi and w (Table 3).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.12.052.Acknowledgments
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